MDC Stock Overview
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.
+ 1 more risk
Medlab Clinical Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$7.65|
|52 Week High||AU$23.25|
|52 Week Low||AU$6.45|
|1 Month Change||-24.26%|
|3 Month Change||-43.75%|
|1 Year Change||-66.00%|
|3 Year Change||-85.22%|
|5 Year Change||-93.33%|
|Change since IPO||-74.50%|
Recent News & Updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For NowOct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?Oct 05
What We Learned About Medlab Clinical's (ASX:MDC) CEO PayFeb 21
Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three YearsDec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near FutureNov 22
|MDC||AU Biotechs||AU Market|
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -1.6% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned -1.8% over the past year.
|MDC Average Weekly Movement||7.3%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||9.0%|
|10% most volatile stocks in AU Market||15.9%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: MDC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MDC's weekly volatility (7%) has been stable over the past year.
About the Company
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.
Medlab Clinical Limited Fundamentals Summary
|MDC fundamental statistics|
Is MDC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDC income statement (TTM)|
|Cost of Revenue||AU$336.29k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.64|
|Net Profit Margin||-541.67%|
How did MDC perform over the long term?See historical performance and comparison